傲農生物(603363.SH)預計2021年度實現歸母淨利潤為虧損10.8億到12.8億元
格隆匯1月28日丨傲農生物(603363.SH)公佈,公司預計2021年年度實現淨利潤為-13.5億元到-16.5億元。
公司預計2021年年度實現歸屬於上市公司股東的淨利潤為-10.8億元到-12.8億元。
公司預計2021年年度實現歸屬於上市公司股東的扣除非經常性損益的淨利潤為-11億元到-13億元。
業績預虧的主要原因:一是今年整體豬價對比去年大幅下跌,飼料原料上漲,公司生豬產業處於較快發展過程中,養殖產能未全部達產,固定費用分攤多,導致短期成本高,養殖板塊大幅虧損;本期淘汰低效母豬數量偏多,淘汰損失較大;二是公司計提存貨跌價、壞賬準備及業績補償款約4.6億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.